Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand Agreement expands Mycovia’s worldwide commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States Mycovia continues to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent vulvovaginal candidiasis DURHAM, N.C.–( COMPANY…

Continue Reading →